Understanding Drug Pricing and the Impact of the Inflation Reduction Act with Jesse Mendelsohn
Welcome to episode 049 of Life Sciences 360.
In this episode of Life Sciences 360, host Harsh Thakkar welcomes Jesse Mendelsohn, Senior Vice President at Model N. Jesse delves into the intricacies of revenue optimization and compliance within the pharmaceutical industry. He shares insights on how Model N’s platform aids pharmaceutical companies in navigating complex pricing, regulatory challenges, and government negotiations.
Chapters :
0:00 – Introduction
1:30 – Welcoming Jesse Mendelsohn
2:00 – Jesse’s Journey with Model N
6:00 – Evolution of Pharma Pricing and Compliance
8:30 – Challenges in Commercial Contracting
12:00 – Regulatory Side of Pharma Pricing
14:30 – Impact of Government as a Major Drug Purchaser
16:00 – Inflation Reduction Act Overview
19:00 – Medicare’s Right to Negotiate Drug Prices
21:00 – Aftershocks of the Inflation Reduction Act
23:30 – Key Takeaways for Pharma Executives
26:00 – Impact on Drug Development Strategy
28:00 – Generics and Biosimilars Market Impact
30:30 – Positive Outcomes of the Inflation Reduction Act
32:00 – What’s Next for Model N
36:00 – Importance of Accurate Data in Pricing
38:30 – Closing Remarks and Connect with Jesse
—–
Links:
* Jesse Mendelsohn LinkedIn
* Model N LinkedIn
* Model N website
*Harsh Thakkar LinkedIn
This article was originally published on Life Sciences Podcast.
